JOE
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Endocrinology (1997) 155, S9-13       DOI: 10.1677/joe.0.155S009
© 1997 Society for Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van der Lely, A.
Right arrow Articles by Lamberts, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van der Lely, A.
Right arrow Articles by Lamberts, S.
Journal of Endocrinology, Vol 155, Issue Suppl_1, S9-13
Copyright © 1997 by Society for Endocrinology


Journal Article

Acromegaly: the significance of serum total and free IGF-I and IGF-binding protein-3 in diagnosis

AJ van der Lely, WW de Herder, JA Janssen, and SW Lamberts


We have studied the physiological and clinical relevance of measurements of serum total and free IGF-I and IGF-binding protein-3 (IGFBP-3) in 57 previously untreated patients with active acromegaly (32 males, 25 females; mean age 47 years) as compared with sex- and age-matched normal healthy controls. Serum total and free IGF-I, but not IGFBP-3, are suitable biochemical parameters for screening for acromegaly. In acromegalics, the mean 24 h serum GH, total IGF-I and IGFBP-3 levels tend to decrease with age. However, in our series of patients, mean 24 h serum GH levels, IGFBP-3, total and free IGF-I do not correlate with disease activity in acromegaly.


This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
W. W de Herder, H R. Taal, P. Uitterlinden, R. A Feelders, J. A M J L Janssen, and A.-J. van der Lely
Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly
Eur. J. Endocrinol., July 1, 2005; 153(1): 67 - 71.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C. Diorio, M. Pollak, C. Byrne, B. Masse, N. Hebert-Croteau, M. Yaffe, G. Cote, S. Berube, C. Morin, and J. Brisson
Insulin-Like Growth Factor-I, IGF-Binding Protein-3, and Mammographic Breast Density
Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1065 - 1073.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
I. E Bonapart, R. van Domburg, S. M T H ten Have, W. W de Herder, R. A M Erdman, J. A M J L Janssen, and A. J. van der Lely
The 'bio-assay' quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations
Eur. J. Endocrinol., February 1, 2005; 152(2): 217 - 224.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
T.-J. Wu, E. H. Yu, L. Song, R. L. Taylor, and P. C. Kao
Filter Paper Collection of Plasma for IGF-I Test in Patients with Acromegaly
Ann. Clin. Lab. Sci., July 1, 2002; 32(3): 287 - 291.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the Society for Endocrinology.